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Abstract This report is a meeting summary of the 2010
Angelman Syndrome Foundation's scientific symposium on
the neuroscience of UBE3A. Angelman syndrome is
characterized by loss of speech, severe developmental
delay, seizures, and ataxia. These core symptoms are
caused by maternal allele disruptions of a single gene—
UBE3A. UBE3A encodes an E3 ubiquitin ligase that
targets certain proteins for proteasomal degradation. This
biology has led to the expectation that the identification of
Ube3a protein targets will lead to therapies for Angelman
syndrome. The recent discovery of Ube3a substrates such
as Arc (activity-regulated cytoskeletal protein) provides
new insight into the mechanisms underlying the synaptic
function and plasticity deficits caused by the loss of Ube3a.
In addition to identifying Ube3a substrates, there have also
been recent advances in understanding UBE3A's integrated
role in the neuronal repertoire of genes and protein
interactions. A developmental picture is now emerging
whereby UBE3A gene dosage on chromosome 15 alters
synaptic function, with deficiencies leading to Angelman





The 2010 scientific symposium was held June 15–16 in
Chapel Hill, NC. The symposium is conducted annually by
the Angelman Treatment and Research Institute, a part of
the Angelman Syndrome Foundation (www.angelman.org).
The theme for this year's symposium was “The Neurosci-
ence of UBE3A from Genes to Behavior.” The program
consisted of invited speakers and other presentations and
was attended by approximately 80 scientists. It became
clear during the conference that Angelman syndrome
research is providing a new vista into the understanding
of neurodevelopmental disorders. Here, we first review
some basic aspects of Angelman syndrome (AS) and then
thematically summarize the meeting presentations.
In normal neurons, UBE3A is transcriptionally inacti-
vated (imprinted) on the paternally derived allele of
chromosome 15 and is active only on the maternally
derived allele. All other somatic cells have biallelic
transcription. In 1997, loss of Ube3a function was
identified as the cause of AS (Kishino et al. 1997; Matsuura
et al. 1997). The syndrome can occur by four different
mutational mechanisms affecting the maternally derived
chromosome 15: intragenic mutation, chromosome micro-
deletion of the gene, paternal uniparental disomy (absence
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DOI 10.1007/s11689-010-9066-zof maternal chromosome 15), and a defect in the imprinting
center that controls UBE3A transcription. The syndrome
occurs in 1:12–15,000 births and is characterized by severe
to profound cognitive delay, seizures, severely limited
speech, pro-social behaviors, tremulous limb movements,
and an ataxic gait (Williams et al. 2010).
UBE3A targets and protein associations
To understand the role of Ube3a and potential therapies for
AS, an important goal is to identify both the substrates that
Ube3a targets for degradation and other Ube3a-interacting
proteins. Moreover, the role of Ube3a must also be
considered in the context of how it and its substrates might
be regulated by neural activity. With this in mind, Michael
E. Greenberg, the symposium's keynote speaker, provided
an overview of how neuronal stimulation induces the
transcription of hundreds of genes, including transcription
factors and genes encoding synaptic proteins, as reviewed
in Greer and Greenberg (2008). An increase in intracellular
calcium appears to be the first step in this gene induction
process. Calcium influx, typically through L-type voltage-
sensitivecalcium channelsandNMDAreceptors,caninitiate
synapse-to-nucleus signaling. Calcium-mediated responses
activate cytoplasmic proteins, including protein kinases,
which translocate to the nucleus to phosphorylate and
activate transcription factors. The cAMP-response element-
binding protein (CREB) was one of the first studied proteins
involved in this type of induction. CREB acts on genes with
CRE-response elements through a repressor complex span-
ning the promoter and upstream elements of these genes.
Calcium-mediated phosphorylation of CREB increases its
association with CREB binding protein and other proteins in
the basal transcription complex to promote gene transcrip-
tion. This intricate process involves changes in histone
acetylation and recruitment of the RNAII polymerase
complex to promote gene transcription.
The Greenberg lab has suggested that UBE3A is itself an
activity-regulated gene (Flavell et al. 2008; Greer et al.
2010) and thus protein substrates of Ube3a would likely
have similar activity-dependent expression. To identify new
UBE3A targets, the Greenberg lab has taken advantage of a
transgenic mouse with a hemagglutinin epitope-tagged
version of ubiquitin (HA-ubiquitin) knocked into the HPRT
locus. By crossing these mice with either wild-type or
Ube3a-deficient mice, and comparing ubiquitination differ-
ences between the two crosses, the investigators were able
to identify direct brain lysate proteins in AS mice that had
reduced HA-ubiquitin tagging. Using this approach, they
identified Sacsin as an Ube3a substrate (mutation in the
Sacsin gene causes autosomal recessive spastic ataxia of
Charlevoix–Saguenay). Then, by comparing sequences
between Sacsin and another known UBE3A substrate,
HHR23A, they identified a UBE3A-binding domain having
loose sequence homology. Using this domain, they identi-
fied Arc (activity-regulated cytoskeletal protein) as a new
UBE3A target (Greer et al. 2010). Arc is known to regulate
AMPA receptor (AMPAR) trafficking and internalization at
the synapse (Bramham et al. 2010). Accordingly, they
found diminished surface counts of synaptic AMPAR
receptors using array tomography (a technique in which
ultra-thin sections of brain tissue are stained, imaged, and
synapses visualized as a 3D reconstruction) and increased
Arc protein levels in direct brain lysate analysis of AS
mouse neurons (which lack Ube3a). The Greenberg lab
hypothesized that the absence of Ube3a could lead to
accumulations of Arc, which in turn could lead to increased
AMPAR internalization. Notably, the converse could occur
in situations of UBE3A excess, as in the 1% of individuals
with autism arising from maternal duplications of the
15q11–q13 region (Christian et al. 2008; Cook et al.
1997), which spans the UBE3A gene. Increased UBE3A
gene expression has been demonstrated for these duplica-
tions, both the interstitial ones and the isodicentric marker
chromosomes (Herzing et al. 2002; Baron et al. 2006).
Interestingly, Arc is known to be translationally inhibited
by the Fragile X protein (FMRP), and the simplistic picture
emerges that dysregulation of Arc protein homeostasis may
be a commonality between AS and Fragile X mental
retardation. It is not clear at this time whether inhibitors of
the metabotropic glutamate 5 receptor, a therapeutic strategy
being pursued in Fragile X, could be of benefit in AS.
Dr. Greenberg also reported on discovery of a new
Ube3a substrate involved with the EphB subfamily of
receptor tyrosine kinases. Eph receptors are known to be
enriched at synapses and are important in regulating
dendritic spine density. The EphB receptors interact with
ephrin ligands and regulate dendritic development through
small GTPases of the Rho family (Rho, Rac, and Cdc42) by
activation of guanine nucleotide exchange factors (GEFs)
(Murai and Pasquale 2003). GEFs serve as a switch to
convert GTPases from an inactive GDP to an active GTP
state. The GTP-bound forms can interact with downstream
effectors that control cytoskeletal rearrangements. EphB-
linked Rho activation appears to inhibit dendritic spine
outgrowth, while Rac activation antagonizes this effect and
promotes outgrowth. Proper dendritic spine formation may
require a balance between actions of these GEFs. The
Greenberg lab determined that a newly identified Ube3a
substrate, named Ephexin 5, acts as a GEF for Rho
(Margolis et al. 2010). Consistent with Ephexin5 being a
Ube3a substrate, Ube3a-deficient neurons exhibit increased
Ephexin 5 levels. This raises the possibility that loss of
UBE3A function could lead to restricted synaptic develop-
ment; conversely, duplication of UBE3A (as seen in some
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with promotion of spine development.
Other labs are also using new, sophisticated technologies
to identify Ube3a substrates. Peter Howley, a long-time
investigator into the role of Ube3a, reported on an unbiased
proteomics approach to identify substrates and regulators of
Ube3a. With most proteomic studies, it is difficult to
determine the physiologically relevant proteins among the
large number of nonspecific interacting proteins dominating
a mass spectral analysis. To overcome this problem, the
Howley lab is collaborating with Wade Harper's lab to
improve the identification of relevant interacting proteins
and the analysis of interaction networks by using a newly
established platform (CompPASS). CompPASS uses cata-
lytically inactive forms of the three major isoforms of
UBE3A to identify high confidence interacting proteins
(Sowa et al. 2009). Initial work with this approach used
human embryonic kidney cells but is now being extended
into human neural cells using a TET-regulatable human
neuroblastoma SH-SY5Y cell line to identify neural-specific
substrates. The expectation is that this new approach will
soon lead to the identification of novel Ube3a substrates,
providing additional therapeutic avenues in AS.
Lawrence T. Reiter reported on his work toward identi-
fying substrates and interacting proteins for the Drosophila
ortholog of UBE3A (dUBE3A). Dr. Reiter used proteomic
profiling in Drosophila heads to show that dUBE3A may
regulate Punch (GTP cyclohydrolase I, GCH1). GCH1
catalyzes the first and rate-limiting step in tetrahydrobiop-
terin biosynthesis and thus is a key regulator of monoamine
(dopamine/serotonin) synthesis in flies and humans. Con-
sequently, dUBE3A overexpression elevates tetrahydro-
biopterin levels while diminished expression of dUBE3A
has the opposite effect on both GCH1 transcripts and
dopamine levels. Dr. Reiter proposed that this regulatory
effect could be due to a transcriptional co-activation function
of dUBE3A since an enzymatically inactive form of
dUBE3A (dUBE3A-C/A) is also able to elevate dopamine
levels through GCH1. Performing rapid genetic and func-
tional assays in Drosophila is an advantage of this model
system, one that has already been used to demonstrate the
importance of UBE3A in dendritic structure (Lu et al. 2009).
Using the more traditional, but still powerful, approach
of yeast-two-hybrid screening and affinity proteomics,
Konstantin Matentzoglu and his group identified the HECT
protein HERC2 as a novel interaction partner of UBE3A.
Interestingly, the HERC2 gene is located in close proximity
to UBE3A and frequently found co-deleted with UBE3A in
individuals with AS. HERC2 contains a HECT and three
Rcc1-like domains (RLDs). The research shows that one of
the RLDs, the Rcc1b domain of HERC2, not only mediates
binding to Ube3a but also greatly enhances Ube3a ligase
activity. Herc2 directly interacts with all three isoforms of
Ube3a. Herc2 recruits Ube3a into complexes and enhances
auto-ubiquitination; furthermore, substrate ubiquitination of
Ring1b appears to be activated in the same manner. The
overlapping tissue distribution of Ube3a and Herc2 sug-
gests a tantalizing possibility for functional interactions,
although the physiological relevance of these potential
interactions remains unknown.
Effects of Ube3a loss on synaptic plasticity, neuron
functions, and cell survival
In addition to the importance of identifying substrates and
interacting partners for Ube3a, another important approach
for guiding therapeutic approaches is to understand the
neurological consequences of reduced Ube3a expression.
Towards this end, Ben Philpot has used a mouse model of
AS to demonstrate that UBE3A is required for neocortical
plasticity in vitro as well as for experience-driven plasticity
in vivo (Yashiro et al. 2009). His work and that of others
demonstrate deficits in AS mouse for long-term potentia-
tion and long-term depression, indicating that the loss of
Ube3a leads to a severe synaptic rigidity that likely
underlies impaired learning in individuals with AS. New
data show that reduced Ube3a causes a loss of synaptic
connectivity across a variety of neuronal cell types and that
this deficit in connectivity may be one of several factors
limiting experience-driven synaptic learning in vivo. The
Philpot lab has previously shown that excitatory synapse
development is blunted in Ube3a-deficient mice by post-
natal day 21. The Philpot lab now finds that there are also
severe deficits in inhibitory synapse development, but these
deficits arise later in development. The deficits in inhibitory
transmission appear to arise from decreased synaptic
contacts made by inhibitory interneurons onto excitatory
pyramidal neurons. It is unclear at this time whether the
change in inhibition is primary or adaptive. However, he
speculated that the loss of inhibition is maladaptive, as the
mice have increased seizure susceptibility that is likely to
arise from a severe loss of inhibition. These observations
suggest that an imbalance between excitation and inhibition
in the neocortex may contribute to epilepsy and neocortical
dysfunction associated with AS.
What might underlie the synaptic and plasticity deficits
observed in Ube3a-deficient mice? Although many factors
are likely to contribute, the increases in Arc expression
observed in Ube3a-deficient mice (noted above) could
explain both the loss of functional synapses, due to the
loss of AMPARs, and deficits in synaptic plasticity, due to
aberrant AMPAR trafficking. Indeed, it is now clear that
Arc expression must be tightly regulated for normal
experience-driven plasticity in learning. Along these lines,
Jason D. Shepherd reported on recent data demonstrating
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plasticity in the developing visual cortex (McCurry et al.
2010). Arc knockout mice exhibited deficits in ocular
dominance plasticity due to deficient depression of the
deprived eye responses, similar to that observed in AS
model mice (Yashiro et al. 2009; Sato and Stryker 2010).
Arc knockout mice also exhibit deficits in stimulus-specific
response potentiation (SRP), a relatively newly identified
form of experience-dependent plasticity (Frenkel et al.
2006). In SRP, daily exposure to a horizontal grating
stimulus of a single orientation selectively potentiates the
amplitude of visual evoked potentials to that orientation,
but not other orientations. These deficits occurred despite
normal visual acuity and retinotopic organization, also
similar to what has been observed in the AS mouse model.
Thus, accumulating data suggest that having either too little
or too much Ube3a, and by extension Arc, causes a severe
impairment in synaptic plasticity.
In addition to plasticity defects, the loss of Ube3a can
alter a number of other neuronal properties. Indeed, Hanoch
Kaphzan reported that the loss of Ube3a alters intrinsic
membrane properties in hippocampal area CA1 neurons.
These changes may be caused, at least in part, by increased
expression of the Na/K-ATPase alpha1 subunit, Ankyrin-B
and Ankyrin-G, all three known to interact with the ATPase
transporter. The Na/K-ATPase transporter consists of alpha
and beta subunits, and at least four genes encode for
different isoforms of the alpha subunits. Missense muta-
tions in the alpha 2 gene (ATP1A2) have been associated
with familial hemiplegic migraine, a disorder in which
some affected individuals can also have seizures and ataxia.
Because Na/K-ATPases play a seminal role in controlling
neuronal excitability, it is tempting to speculate that the
observed abnormalities could be related to the seizure
liability observed in individuals with AS.
Simone Küehnle used established non-neural mammali-
an cell lines and RNAi-mediated downregulation of Ube3a
to demonstrate that reduced Ube3a levels result in severe
cytotoxicity. He also found that ectopic Ube3a expression is
cytotoxic too, indicating that Ube3a levels have to be
delicately balanced in mammalian cells, contributing once
again to the recurring theme that either the loss or
overexpression of Ube3a can lead to many similar defects.
He then performed studies showing that, for cells depleted
for Ube3a, CaMKII overexpression can partially rescue the
cytotoxic phenotype. CaMKII activity is known to be
perturbed in AS mouse neurons (Weeber et al. 2003).
Hence, the cytotoxicity of Ube3a depletion, as observed in
non-neuronal cell lines, may at least in part involve the
same pathways that are deregulated in the AS mouse
model. Dr. Küehnle's research with established cell lines
may be of potential use to elucidate the pathways involved
in AS development.
New mouse models of Angelman syndrome and Ube3a
imprinting
Future advances in AS will rely heavily on the development
of new mouse models and their creative use. Scott Dindot
has developed an Ube3a-YFP reporter mouse (Dindot et al.
2008) and is now using crosses of this mouse having the
YFP reporter on either the maternal or paternal allele to
examine the allelic expression patterns of Ube3a during
neurogenesis. Current observations suggest that both pater-
nal and maternal alleles express Ube3a in the stem cell
niches lining the lateral ventricles and in the dentate gyrus of
the hippocampal formation. Progenitor cells and immature
neurons both express Ube3a, while expression of Ube3a in
mature neurons is derived primarily from the maternal allele.
Notably, low levels of expression were detected from the
paternal allele, demonstrating that the paternal allele remains
functional and intact. Collectively, these data suggest that
imprinting of Ube3a is specific to neuronal cells, as
previously reported (Yamasaki et al. 2003), but is not
complete until the later stages of neuronal maturation.
While most mouse models of AS have involved selective
deletion of Ube3a (Jiang et al. 1998; Miura et al. 2002),
70% of individuals with AS have a much larger deletion
from 15q11 to q13. To create a more realistic model of the
most common form of AS, Yong-Hui Jiang and his cow-
orkers generated mutant mice with a 1.6 Mb chromosomal
deletion that spans Ube3a to Gabrb3, including deletion of
Atp10a. Homozygous deletion mice show cleft palate and
die in the perinatal period, but the heterozygotes survive and
show parent-of-origin phenotypes (Jiang et al. 2010).
Expression analysis of maternal and paternal deletion mice
confirmed that the Ube3a gene is exclusively maternally
expressed in brain and that the Atp10a and Gabrb3 genes are
biallelically expressed in all brain subregions studied. The
maternal deletion mice showed many of the behavioral
features seen in other Ube3a-deficient mouse models. In
addition, ultrasonic vocalization recordings in newborns
revealed that maternal deletion pups emitted significantly
more vocalizations than wild-type littermates, but the
behavioral correlate to communication deficits observed in
human ASisunclear.Thismousemodelwillbeinvaluableto
future AS research and will help to provide a biological basis
for the more severe deficits in speech and epilepsy observed
in AS individuals with 15q11–q13 deletions compared to
those with Ube3a mutations (Lossie et al. 2001).
Induced pluripotent stem cells, gene transcription,
and vector strategies
New technologies in biomedical research show promise in
advancing our understanding on AS. Marc Lalande ele-
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induced pluripotent stem (iPS) cells to develop an innova-
tive approach to study AS. Their lab has established two
human AS deletion and two normal control iPS cell lines
derived from fibroblasts (Chamberlain et al. 2010). The iPS
cell lines express NANOG and OCT4, two markers that
characterize the undifferentiated stem cell state. The iPS
cell lines can be differentiated into mature neurons, using a
technique that mimics neural development in the embryo.
During this process of in vitro neurogenesis, there is
upregulation of PAX6, a marker of neuronal precursors, at
early stages, followed by expression of MAP2, Synapsin I
and III tubulin in neurons. Single-cell recordings from the
iPS-derived neurons demonstrate that these cells fire action
potentials and exhibit spontaneous synaptic activity, hall-
marks of mature neurons. A marked decrease in Ube3a
mRNA and protein is observed in neurons derived from AS
iPS cells, indicating that silencing of the paternal UBE3A
allele occurs in this in vitro platform, similar to what is
likely to occur in vivo. AS neurons derived from iPS cell
lines may thus provide important insights about the
developmental timing and regulation of UBE3A imprinting
and for characterizing the functional abnormalities in
human AS neurons.
The imprinting of Ube3a presents unique treatment
opportunities. One strategy for developing an AS therapeu-
tic is to activate the silenced, but intact, paternal Ube3a
allele. Towards this end, Barbara Bailus presented an
update on work with David Segal in developing artificial
transcription factors (ATFs) that may serve such a purpose.
By attaching an activation or repression domain to a zinc
finger construct, an ATF is formed that can enhance or
suppress transcriptional activity. Two approaches are being
explored to activate the paternal copy of murine Ube3a in
mouse cells. The direct approach targets an activator ATF to
the promoter region of the paternal Ube3a, while the
indirect approach will use repressor ATFs to silence the
Ube3a antisense transcript thought to silence the paternal
copy of Ube3a. While still preliminary, this approach
represents a promising new front on the development of
AS therapeutics.
Clearly, a number of approaches to develop AS
therapeutics rely on methodologies that restore normal
Ube3a levels in individuals with AS. To explore the
possibility that this might be achievable with advances in
gene therapy, Ron Mandel reviewed the use of recombinant
adeno-associated viral vectors (rAAV) for adjusting gene
expression in the brain. Transduction efficiency has steadily
increased since the first use of the rAAV vectors in 1996.
To date, rAAV2 has been used in five human clinical trials
for neurological disorders. As rAAV2 production methods
have improved, the purity of the vector and the amount
recovered through the production process has increased. In
addition, with the advent of alternative AAV capsid
serotypes, vector titers have increased, and brain transduc-
tion has become more efficient. Nevertheless, there continue
to be considerable problems in achieving global cellular
transduction. Neurons that are transduced (glial cells do not
become transduced) have generally robust and durable gene
expression. The rAAV has a size constraint of approximately
5 kb of genomic code (including the promoter), the
approximate size of the UBE3A cDNA, so packaging may
be difficult. Also, gene copy number varies widely in
transducedneurons, and this may be problematic forUBE3A
since both diminished and increased cellular levels of Ube3a
appear to be harmful. While gene therapy may not present a
readily viable option for restoring Ube3a levels in the brain
and treating AS, the expectation is that advances in gene
therapy may someday make this approach viable.
Human clinical and behavioral studies
Mark Nespeca provided an overview of the clinical conun-
drums associated with epilepsy in AS. There is no salient
hypothesis as to why seizures are so prevalent in the
syndrome, and the clinical treatment with anticonvulsants
remains largely empirical but fairly effective. To date, no
class of anticonvulsants has shown a clearly superior
benefit. Thus, an important future goal is to understand
the pathophysiology underlying the severe and relatively
intractable forms of epilepsy in AS so that more rationally
based anticonvulsants can be designed.
Due to the relative rarity of AS, best treatment practices
are often derived from extensive parent questionnaires.
With this in mind, Sarika Peters provided an update of a
web-based parent questionnaire project aimed at delineating
the use of traditional and alternative treatments for
challenging behaviors in AS. More than half (53% of
333) the caregivers reported individuals with AS using at
least one alternative treatment. The most popular alternative
treatments included melatonin, omega-3 fatty acids/fish oil,
folic acid, and magnesium. However, the efficacy of these
approaches still needs to be studied under rigorous control
conditions, as was recently done by Peters et al. (2010) for
analysis of folic acid and betaine as a putative AS
therapeutic. In addition to using surveys to help determine
best practices in AS, surveys have also helped to highlight
the remarkable strain on caregivers. Frances Ulman
presented results from an online anonymous questionnaire
survey investigating parenting experiences in mothers of a
child with a developmental handicap. A total of 211
mothers completed the questionnaire and, of the sample,
30 had a child with AS. Mothers of a child with AS
demonstrated a unique profile of caregiving experiences,
including devoting significantly greater time to caregiving
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develop therapies that can alleviate the behavioral issues
surrounding Angelman syndrome, and great consideration
needs to be given to the extreme challenges of being a
caregiver.
A common misperception is that individuals with AS are
incapable of learning. Jane Summers is helping to debunk
this misperception. She reported on her efforts to develop a
behavioral battery to assess memory, motor imitation, and
motor performance skills in individuals with AS. She studied
12 children, ages 3.6 to 12.7 years, and used structured and
reproducible assessment protocols. Her work demonstrates
that there are a range of abilities among individuals with AS
and some individuals exhibit relatively well-developed
motor performance skills and an ability to reproduce actions
from memory. Participants' skill levels were tested several
times and remained stable over the assessment period. This
work provides a way to evaluate key learning skills in
individuals with AS and study the impact of different
therapeutic approaches on their ability to learn.
More details of the findings from the conference are
available in the abstracts at the Angelman Syndrome
Foundation website (www.angelman.org).
Conclusion
We are gaining a better understanding of the biological
actions of UBE3A as more neuroscientists investigate its
role in neural plasticity and learning. Newly discovered
UBE3A targets and interacting proteins are creating
speculation about therapeutic, drugable targets, and this is
an exciting change in the research landscape for AS. While
deficiency of Ube3a in brain causes AS, overexpression
appears to be associated with intellectual impairments and
developmental abnormalities in the autism spectrum.
Whether an increase in Ube3a dosing alone is the primary
cause for the autism symptomatology is currently unknown.
Continued research into the area of autism may thus bring
better understanding about AS, and continued research on
UBE3A's role in AS may likewise bring benefits to those
with autism.
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